Cargando…
Cross-Match as an Immuno-Oncological Risk Factor for Hepatocellular Carcinoma Recurrence and Inferior Survival After Living Donor Liver Transplantation: A Call for Further Investigation
BACKGROUND: The success of immunotherapy for patients with hepatocellular carcinoma (HCC) suggests that immune dysregulation occurs in HCC patients. This warrants an immuno-oncological risk assessment in the platform of liver transplantation. METHODS: This retrospective single-center study analyzed...
Autores principales: | Ho, Cheng-Maw, Hu, Rey-Heng, Wu, Yao-Ming, Ho, Ming-Chih, Lee, Po-Huang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731698/ https://www.ncbi.nlm.nih.gov/pubmed/33343205 http://dx.doi.org/10.1177/1179554920968774 |
Ejemplares similares
-
Long-Term Survival in Patients With T2 Hepatocellular Carcinoma After Primary Curative Resection Can Be Further Stratified by Tumor Size
por: Ho, Cheng-Maw, et al.
Publicado: (2014) -
Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma
por: Yang, Po-Chih, et al.
Publicado: (2016) -
Delayed Hepatocellular Carcinoma Recurrence After Liver Transplantation: Comprehensive Clinical Characterization of Case Series
por: Wong, Ta-Hsiang, et al.
Publicado: (2022) -
Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective
por: Ho, Cheng-Maw, et al.
Publicado: (2019) -
Survival After Treatable Hepatocellular Carcinoma Recurrence in Liver Recipients: A Nationwide Cohort Analysis
por: Ho, Cheng-Maw, et al.
Publicado: (2021)